Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients

NCT04029272 on ClinicalTrials.gov · last registry update 2019-07-23

80 participants. Its estimated completion date, 28 February 2020, has passed with no update to the record. Primary outcome, as filed: Change in body weight. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. exenatide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Peking Union Medical College Hospital
Sponsor type: Other
Enrollment: 80
Started: 2019-07-20
Primary completion: 2020-02-28 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in body weight

Conditions studied

Polycystic Ovary Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.